49. Systemic lupus erythematosus
827 clinical trials,   638 drugs   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1800015030
2018-03-012018-03-01A Clinical Trial on Safety and effect of Dapagliflozin to Control Blood Glucose Levels in Systemic Lupus ErythematosusThe Safety of SGLT2-i Dapagliflozin on Treating Blood Glucose Levels in SLE Systemic Lupus ErythematosusCase series:add-on or replace dapagliflozin;Dept. Rheumatology, Renji Hospital South CampusNULLPending1870BothCase series:35;4 (Phase 4 study)China
2NCT03296995
(ClinicalTrials.gov)
July 1, 201725/9/2017Accuracy, Feasibility and Acceptance of CGM LupusAccuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Systemic Lupus ErythematosusSystemic Lupus Erythematosus;Critical Illness;Diabetic Blood Glucose MonitoringDevice: Flash glucose monitoring systemRenJi HospitalNULLRecruiting18 YearsN/AAll30N/AChina
3NCT01217320
(ClinicalTrials.gov)
January 20116/10/2010Creatine Supplementation in Pediatric RheumatologyEfficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile DermatomyositisJuvenile Systemic Lupus Erythematosus;Juvenile DermatomyositisDietary Supplement: creatine;Dietary Supplement: placebo (dextrose)University of Sao PauloNULLRecruiting6 Years18 YearsBoth40N/ABrazil
4NCT00029926
(ClinicalTrials.gov)
January 200226/1/2002Positron Emission Tomography (PET) to Locate Areas of White Blood Cell ActivityA Pilot Study of F-18FDG Positron Emission Tomography (PET) to Assess the Distribution of Activated Lymphocytes in Systemic Lupus Erythematosus (SLE)Lupus Erythematosus;SystemicDrug: 2-deoxy-2 [F-18] fluoro-2-d-glucoseNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NULLCompletedN/AN/ABoth20N/AUnited States